Skip to main content

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MO, MYGN and YJ

NEW YORK, NY / ACCESSWIRE / November 18, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Altria Group, Inc. (NYSE:MO)
Class Period: December 20, 2018 to September 24, 2019
Lead Plaintiff Deadline: December 2, 2019

The lawsuit alleges Altria Group, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Altria had conducted insufficient due diligence into JUUL prior to the Company's $12.8 billion investment, or 35% stake, in JUUL; (ii) Altria consequently failed to inform investors, or account for, material risks associated with JUUL's products and marketing practices, and the true value of JUUL and its products; (iii) all of the foregoing, as well as mounting public scrutiny, negative publicity, and governmental pressure on e-vapor products and JUUL made it reasonably likely that Altria's investment in JUUL would have a material negative impact on the Company's reputation and operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in MO: http://www.kleinstocklaw.com/pslra-1/altria-group-inc-loss-submission-form?id=4470&from=1

Myriad Genetics, Inc. (NASDAQ:MYGN)
Class Period: September 2, 2016 to August 13, 2019
Lead Plaintiff Deadline: November 26, 2019

Throughout the class period, Myriad Genetics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in MYGN: http://www.kleinstocklaw.com/pslra-1/myriad-genetics-inc-loss-submission-form?id=4470&from=1

Yunji Inc. (NASDAQ:YJ)
Class Period: on behalf of shareholders who purchased or otherwise acquired Yunji American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's May 2019 initial public offering.
Lead Plaintiff Deadline: January 13, 2020

Yunji Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was shifting certain of its sales to its marketplace platform; (2) this supply chain restructuring was likely to disrupt Yunji's relationships with suppliers; (3) this supply chain restructuring was likely to have an adverse impact on the Company's financial results; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in YJ: http://www.kleinstocklaw.com/pslra-1/yunji-inc-loss-submission-form?id=4470&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/567192/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-MO-MYGN-and-YJ

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.